Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Christoph Winkler
No abstract text is available yet for this article.
April 27, 2024: New England Journal of Medicine
#2
JOURNAL ARTICLE
Merlin Chowkwanyun
No abstract text is available yet for this article.
April 27, 2024: New England Journal of Medicine
#3
EDITORIAL
Trevor Mundel
No abstract text is available yet for this article.
April 26, 2024: New England Journal of Medicine
#4
JOURNAL ARTICLE
Kassoum Kayentao, Aissata Ongoiba, Anne C Preston, Sara A Healy, Zonghui Hu, Jeff Skinner, Safiatou Doumbo, Jing Wang, Hamidou Cisse, Didier Doumtabe, Abdrahamane Traore, Hamadi Traore, Adama Djiguiba, Shanping Li, Mary E Peterson, Shinyi Telscher, Azza H Idris, William C Adams, Adrian B McDermott, Sandeep Narpala, Bob C Lin, Leonid Serebryannyy, Somia P Hickman, Andrew J McDougal, Sandra Vazquez, Matthew Reiber, Judy A Stein, Jason G Gall, Kevin Carlton, Philipp Schwabl, Siriman Traore, Mamadou Keita, Amatigué Zéguimé, Adama Ouattara, M'Bouye Doucoure, Amagana Dolo, Sean C Murphy, Daniel E Neafsey, Silvia Portugal, Abdoulaye Djimdé, Boubacar Traore, Robert A Seder, Peter D Crompton
BACKGROUND: Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal antibody administered subcutaneously can protect children from P. falciparum infection in a region where this organism is endemic is unclear. METHODS: We conducted a phase 2 trial in Mali to assess the safety and efficacy of subcutaneous administration of L9LS in children 6 to 10 years of age over a 6-month malaria season...
April 26, 2024: New England Journal of Medicine
#5
JOURNAL ARTICLE
Haydar Frangoul, Franco Locatelli, Akshay Sharma, Monica Bhatia, Markus Mapara, Lyndsay Molinari, Donna Wall, Robert I Liem, Paul Telfer, Ami J Shah, Marina Cavazzana, Selim Corbacioglu, Damiano Rondelli, Roland Meisel, Laurence Dedeken, Stephan Lobitz, Mariane de Montalembert, Martin H Steinberg, Mark C Walters, Michael J Eckrich, Suzan Imren, Laura Bower, Christopher Simard, Weiyu Zhou, Fengjuan Xuan, Phuong Khanh Morrow, William E Hobbs, Stephan A Grupp
BACKGROUND: Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) at the erythroid-specific enhancer region of BCL11A . METHODS: We conducted a phase 3, single-group, open-label study of exa-cel in patients 12 to 35 years of age with sickle cell disease who had had at least two severe vaso-occlusive crises in each of the 2 years before screening...
April 24, 2024: New England Journal of Medicine
#6
JOURNAL ARTICLE
George Q Daley
No abstract text is available yet for this article.
April 24, 2024: New England Journal of Medicine
#7
EDITORIAL
Joseph M McCune, Hans-Peter Kiem
No abstract text is available yet for this article.
April 24, 2024: New England Journal of Medicine
#8
LETTER
Angela Yen, Zachary Zappala, Rebecca S Fine, Timothy D Majarian, Parin Sripakdeevong, David Altshuler
No abstract text is available yet for this article.
April 24, 2024: New England Journal of Medicine
#9
JOURNAL ARTICLE
Franco Locatelli, Peter Lang, Donna Wall, Roland Meisel, Selim Corbacioglu, Amanda M Li, Josu de la Fuente, Ami J Shah, Ben Carpenter, Janet L Kwiatkowski, Markus Mapara, Robert I Liem, Maria Domenica Cappellini, Mattia Algeri, Antonis Kattamis, Sujit Sheth, Stephan Grupp, Rupert Handgretinger, Puja Kohli, Daoyuan Shi, Leorah Ross, Yael Bobruff, Christopher Simard, Lanju Zhang, Phuong Khanh Morrow, William E Hobbs, Haydar Frangoul
BACKGROUND: Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis through ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing of the erythroid-specific enhancer region of BCL11A in autologous CD34+ hematopoietic stem and progenitor cells (HSPCs). METHODS: We conducted an open-label, single-group, phase 3 study of exa-cel in patients 12 to 35 years of age with transfusion-dependent β-thalassemia and a β0 /β0 , β0 /β0 -like, or non-β0 /β0 -like genotype...
April 24, 2024: New England Journal of Medicine
#10
JOURNAL ARTICLE
Joshua M Sharfstein, Lawrence O Gostin
No abstract text is available yet for this article.
April 24, 2024: New England Journal of Medicine
#11
JOURNAL ARTICLE
Kevin Schulman, Barak Richman
New England Journal of Medicine, Volume 390, Issue 16, Page 1445-1447, April 25, 2024.
April 20, 2024: New England Journal of Medicine
#12
JOURNAL ARTICLE
Zongli Han, Yanli Du
New England Journal of Medicine, Volume 390, Issue 16, April 25, 2024.
April 20, 2024: New England Journal of Medicine
#13
JOURNAL ARTICLE
Louise Aronson
New England Journal of Medicine, Volume 390, Issue 16, Page 1451-1453, April 25, 2024.
April 20, 2024: New England Journal of Medicine
#14
LETTER
Allison Lind, Susan M Mason, Elizabeth Wrigley-Field
No abstract text is available yet for this article.
April 19, 2024: New England Journal of Medicine
#15
JOURNAL ARTICLE
Ezekiel J Emanuel, Johan L Dellgren, Matthew S McCoy, Govind Persad
No abstract text is available yet for this article.
April 17, 2024: New England Journal of Medicine
#16
JOURNAL ARTICLE
Carlos Carazo Casas, Marimar Medina Gonzalez
New England Journal of Medicine, Volume 390, Issue 15, April 2024.
April 13, 2024: New England Journal of Medicine
#17
JOURNAL ARTICLE
Jeni Miller, Courtney Howard, Lujain Alqodmani
New England Journal of Medicine, Volume 390, Issue 15, Page 1354-1356, April 2024.
April 13, 2024: New England Journal of Medicine
#18
JOURNAL ARTICLE
Nishant Uppal, Zirui Song
No abstract text is available yet for this article.
April 10, 2024: New England Journal of Medicine
#19
JOURNAL ARTICLE
Charlene A Wong, Debra Houry, Mandy K Cohen
No abstract text is available yet for this article.
April 10, 2024: New England Journal of Medicine
#20
JOURNAL ARTICLE
Stefan Blankenberg, Moritz Seiffert, Reinhard Vonthein, Helmut Baumgartner, Sabine Bleiziffer, Michael A Borger, Yeong-Hoon Choi, Peter Clemmensen, Jochen Cremer, Martin Czerny, Nina Diercks, Ingo Eitel, Stephan Ensminger, Derk Frank, Norbert Frey, Andreas Hagendorff, Christian Hagl, Christian Hamm, Utz Kappert, Matthias Karck, Won-Keun Kim, Inke R König, Markus Krane, Ulf Landmesser, Axel Linke, Lars S Maier, Steffen Massberg, Franz-Josef Neumann, Hermann Reichenspurner, Tanja K Rudolph, Christof Schmid, Holger Thiele, Raphael Twerenbold, Thomas Walther, Dirk Westermann, Erion Xhepa, Andreas Ziegler, Volkmar Falk
BACKGROUND: Among low-risk patients with severe, symptomatic aortic stenosis who are eligible for both transcatheter aortic-valve implantation (TAVI) and surgical aortic-valve replacement (SAVR), data are lacking on the appropriate treatment strategy in routine clinical practice. METHODS: In this randomized noninferiority trial conducted at 38 sites in Germany, we assigned patients with severe aortic stenosis who were at low or intermediate surgical risk to undergo either TAVI or SAVR...
April 8, 2024: New England Journal of Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
